Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DESTINY-Biliary Tract Cancer-01
CTR20250023Phase 3Active
- Sponsor
- AstraZeneca
- Start
- Feb 2025
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of trastuzumab deruxtecan, rilvegostomig in biliary cancer, sponsored by AstraZeneca. Started Feb 2025; status: active.
02
Drugs
trastuzumab deruxtecanrilvegostomig
03
Conditions
biliary cancer
Beyond the preview
Go deeper on CTR20250023.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20250023.